Innate Pharma S.A [IPH] vs Valneva SE [VLA] Detailed Stock Comparison
Innate Pharma S.A
Euronext
Loading...
Valneva SE
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Innate Pharma S.A wins in 3 metrics, Valneva SE wins in 13 metrics, with 0 ties. Valneva SE appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Innate Pharma S.A | Valneva SE | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -2.94 | 70.64 | Innate Pharma S.A |
| Price-to-Book Ratio | 17.31 | 3.38 | Valneva SE |
| Debt-to-Equity Ratio | 350.86 | 105.63 | Valneva SE |
| PEG Ratio | N/A | -10.22 | N/A |
| EV/EBITDA | -2.17 | -20.10 | Valneva SE |
| Profit Margin (TTM) | -245.87% | -34.15% | Valneva SE |
| Operating Margin (TTM) | -324.87% | -22.01% | Valneva SE |
| Return on Equity | -162.91% | -38.02% | Valneva SE |
| Return on Assets (TTM) | -22.52% | -6.58% | Valneva SE |
| Free Cash Flow (TTM) | $-7.29M | $-83.66M | Innate Pharma S.A |
| 1-Year Return | -15.23% | 68.77% | Valneva SE |
| Price-to-Sales Ratio (TTM) | 8.55 | 3.31 | Valneva SE |
| Enterprise Value | $109.10M | $671.64M | Valneva SE |
| EV/Revenue Ratio | 5.42 | 3.42 | Valneva SE |
| Gross Profit Margin (TTM) | N/A | 50.10% | N/A |
| Revenue per Share (TTM) | $0 | $1 | Valneva SE |
| Earnings per Share (Diluted) | $-0.61 | $-0.46 | Valneva SE |
| Beta (Stock Volatility) | 0.91 | 1.01 | Innate Pharma S.A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Innate Pharma S.A vs Valneva SE Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Innate Pharma S.A | -5.45% | -5.65% | -16.08% | 0.60% | -11.64% | -11.64% |
| Valneva SE | 1.62% | 9.77% | -15.78% | 75.72% | 31.79% | 84.85% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Innate Pharma S.A | -15.23% | -28.33% | -45.60% | -87.38% | 1.21% | 1.21% |
| Valneva SE | 68.77% | -24.82% | -38.21% | 31.38% | -17.41% | -17.41% |
News Based Sentiment: Innate Pharma S.A vs Valneva SE
Innate Pharma S.A
News based Sentiment: MIXED
September brought both positive analyst coverage and revised launch timelines for Innate Pharma, creating a mixed investment picture. While the company is actively engaging with investors and providing transparency, the delayed launches introduce uncertainty, making it a moderately significant month for investors.
Valneva SE
News based Sentiment: NEGATIVE
September was a pivotal month for Valneva, dominated by the FDA suspension of its IXCHIQ vaccine. While positive Lyme disease vaccine data and a Q2 earnings beat offered some respite, the regulatory setback and subsequent financial revisions significantly overshadow these developments, creating a challenging outlook for investors.
Performance & Financial Health Analysis: Innate Pharma S.A vs Valneva SE
| Metric | IPH | VLA |
|---|---|---|
| Market Information | ||
| Market Cap | €169.76M | €649.14M |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 89,688 | 1,037,300 |
| 90 Day Avg. Volume | 121,635 | 2,145,825 |
| Last Close | €1.67 | €4.27 |
| 52 Week Range | €1.33 - €2.50 | €1.73 - €5.41 |
| % from 52W High | -33.36% | -21.18% |
| All-Time High | €17.85 (Apr 20, 2015) | €29.70 (Nov 29, 2021) |
| % from All-Time High | -90.64% | -85.62% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.64% | 0.27% |
| Quarterly Earnings Growth | N/A | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | -2.46% | -0.34% |
| Operating Margin (TTM) | -3.25% | -0.22% |
| Return on Equity (TTM) | -1.63% | -0.38% |
| Debt to Equity (MRQ) | 350.86 | 105.63 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €0.11 | €1.12 |
| Cash per Share (MRQ) | €0.88 | €0.97 |
| Operating Cash Flow (TTM) | €-6,896,000 | €-11,900,000 |
| Levered Free Cash Flow (TTM) | €17.12M | €-34,380,124 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Innate Pharma S.A vs Valneva SE
| Metric | IPH | VLA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -2.94 | 70.64 |
| Forward P/E | 1.00 | -10.22 |
| PEG Ratio | N/A | -10.22 |
| Price to Sales (TTM) | 8.55 | 3.31 |
| Price to Book (MRQ) | 17.31 | 3.38 |
| Market Capitalization | ||
| Market Capitalization | €169.76M | €649.14M |
| Enterprise Value | €109.10M | €671.64M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.42 | 3.42 |
| Enterprise to EBITDA | -2.17 | -20.10 |
| Risk & Other Metrics | ||
| Beta | 0.91 | 1.01 |
| Book Value per Share (MRQ) | €0.11 | €1.12 |
Financial Statements Comparison: Innate Pharma S.A vs Valneva SE
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IPH | VLA |
|---|---|---|
| Revenue/Sales | N/A | €49.23M |
| Cost of Goods Sold | N/A | €23.04M |
| Gross Profit | N/A | €26.19M |
| Research & Development | N/A | €14.95M |
| Operating Income (EBIT) | N/A | €-5.96M |
| EBITDA | N/A | €-5.45M |
| Pre-Tax Income | N/A | €-7.76M |
| Income Tax | N/A | €1.47M |
| Net Income (Profit) | N/A | €-9.23M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IPH | VLA |
|---|---|---|
| Cash & Equivalents | €66.40M | €152.99M |
| Total Current Assets | €85.74M | €287.05M |
| Total Current Liabilities | €32.98M | €106.20M |
| Long-Term Debt | €22.29M | €188.74M |
| Total Shareholders Equity | €8.83M | €175.25M |
| Retained Earnings | €-386.36M | €-573.16M |
| Property, Plant & Equipment | €2.86M | €154.31M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IPH | VLA |
|---|---|---|
| Operating Cash Flow | N/A | €-7.74M |
| Capital Expenditures | N/A | €-1.40M |
| Free Cash Flow | N/A | €-9.62M |
| Debt Repayment | N/A | €-685,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IPH | VLA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 89,688 | 1,037,300 |
| Average Daily Volume (90 Day) | 121,635 | 2,145,825 |
| Shares Outstanding | 83.81M | 162.40M |
| Float Shares | 59.22M | 126.75M |
| % Held by Insiders | 0.30% | 0.12% |
| % Held by Institutions | 0.10% | 0.23% |
Dividend Analysis & Yield Comparison: Innate Pharma S.A vs Valneva SE
| Metric | IPH | VLA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |